Clinical Trial Update: A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 study evaluating Nipocalimab to reduce fetal and neonatal alloimmune thrombocytopenia (FNAIT). The trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fetal and Neonatal Alloimmune Thrombocytopenia

Drugs mentioned

• Nipocalimab (nipocalimab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Thrombocytopenia, Neonatal Alloimmune | Phase 3 | Status: RECRUITING